AE Wealth Management LLC cut its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 24.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,142 shares of the company’s stock after selling 1,323 shares during the quarter. AE Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $260,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Brave Asset Management Inc. raised its position in CRISPR Therapeutics by 40.0% during the fourth quarter. Brave Asset Management Inc. now owns 3,500 shares of the company’s stock worth $265,000 after acquiring an additional 1,000 shares in the last quarter. Itau Unibanco Holding S.A. grew its position in shares of CRISPR Therapeutics by 142.1% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,954 shares of the company’s stock valued at $154,000 after acquiring an additional 1,147 shares during the period. Concord Wealth Partners increased its stake in shares of CRISPR Therapeutics by 277.3% during the 4th quarter. Concord Wealth Partners now owns 796 shares of the company’s stock worth $60,000 after purchasing an additional 585 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $43,865,000. Finally, Rockefeller Capital Management L.P. lifted its stake in CRISPR Therapeutics by 38.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 23,662 shares of the company’s stock valued at $1,792,000 after purchasing an additional 6,569 shares during the last quarter. 56.12% of the stock is owned by institutional investors and hedge funds.
Several research firms have issued reports on CRSP. BMO Capital Markets assumed coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They issued an “outperform” rating and a $98.00 price objective on the stock. Royal Bank of Canada reduced their price objective on shares of CRISPR Therapeutics from $95.00 to $85.00 in a research report on Tuesday, May 10th. Credit Suisse Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, April 28th. They issued a “neutral” rating and a $78.00 price objective on the stock. Barclays reduced their target price on shares of CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. Finally, Oppenheimer decreased their price target on shares of CRISPR Therapeutics from $150.00 to $122.00 and set an “outperform” rating on the stock in a research note on Thursday, June 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $114.31.
In related news, CEO Samarth Kulkarni sold 25,000 shares of the company’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $61.59, for a total transaction of $1,539,750.00. Following the completion of the sale, the chief executive officer now owns 290,279 shares of the company’s stock, valued at $17,878,283.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.70% of the stock is owned by insiders.
Shares of CRSP stock opened at $79.05 on Wednesday. The stock has a market cap of $6.12 billion, a P/E ratio of 21.90 and a beta of 1.91. CRISPR Therapeutics AG has a 1 year low of $42.51 and a 1 year high of $144.73. The stock has a 50 day simple moving average of $60.97 and a 200 day simple moving average of $62.14.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.91) by ($0.41). The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. CRISPR Therapeutics’s revenue was up 74.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.51) earnings per share. On average, equities research analysts predict that CRISPR Therapeutics AG will post -8.98 earnings per share for the current fiscal year.
CRISPR Therapeutics Profile (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.